A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with psoriasis
Phase 4
- Conditions
- psoriasis
- Registration Number
- JPRN-UMIN000005310
- Lead Sponsor
- Department of Dermatology, Kawasaki Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with severe infection, active tuberculosis, history of allergy to ingredients of infliximab or to proteins derived from mouse, demyelinating diseases and its past history and congestive heart failure. Carrier of hepatitis B virus. Patients who have a plan of immunization with vaccine.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum concentration of infliximab should be examined from blood samples drawn before and 30 minutes after each infusion of 0 and 2, 6, 14, 22 weeks. Serum anti-infliximab antibody will be examined from serum sample before each infusion.
- Secondary Outcome Measures
Name Time Method PASI score should be recorded before each infusion of 0 and 2, 6, 14, 22 weeks.